SKIV2L2 Antibody [Allophycocyanin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-45345APC
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human, Mouse
Applications
ELISA, Immunohistochemistry, Western Blot
Label
Allophycocyanin (Excitation = 620-650 nm, Emission = 660-670 nm)
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
superkiller viralicidic activity 2-like 2. (Uniprot# P42285)
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for SKIV2L2 Antibody [Allophycocyanin]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: SKIV2L2
Alternate Names
ATP-dependent helicase SKIV2L2, Dob1, EC 3.6.1, EC 3.6.4.13, fSAP118, KIAA0052functional spliceosome-associated protein 118, MGC142069, Mtr4superkiller viralicidic activity 2-like 2, superkiller viralicidic activity 2-like 2 (S. cerevisiae)
Gene Symbol
MTREX
Additional SKIV2L2 Products
Product Documents for SKIV2L2 Antibody [Allophycocyanin]
Product Specific Notices for SKIV2L2 Antibody [Allophycocyanin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...